19891-06-6 Usage
Description
(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-3-[(benzoyloxy)methyl]-4a,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibenzoate is a complex organic molecule with a cyclopropa[3,4]benzo[1,2-e]azulene core. It features a benzoyloxy group, tetramethylated hydroxyl groups, and two benzoate ester groups. This unique structural composition endows it with potential applications in pharmaceuticals and organic synthesis, making it a promising candidate for drug design and material science.
Uses
Used in Pharmaceutical Industry:
(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-3-[(benzoyloxy)methyl]-4a,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibenzoate is used as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with novel mechanisms of action and improved therapeutic profiles.
Used in Organic Synthesis:
In the field of organic synthesis, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-3-[(benzoyloxy)methyl]-4a,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibenzoate serves as a versatile building block for the creation of various organic compounds. Its diverse functional groups enable a wide range of chemical reactions, facilitating the synthesis of complex molecules with potential applications in various industries.
Used in Drug Design:
(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-3-[(benzoyloxy)methyl]-4a,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibenzoate is used as a structural template in drug design. Its unique arrangement of atoms and functional groups can be exploited to create new drugs with improved efficacy, selectivity, and safety profiles. This molecule can be further modified and optimized to target specific biological pathways and treat various diseases.
Used in Material Science:
In the realm of material science, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-3-[(benzoyloxy)methyl]-4a,7b-dihydroxy-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibenzoate has potential applications in the development of novel materials with unique properties. Its structural features can be utilized to create materials with enhanced stability, reactivity, or selectivity, which can be applied in various industries such as electronics, energy, and environmental protection.
Check Digit Verification of cas no
The CAS Registry Mumber 19891-06-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,8,9 and 1 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 19891-06:
(7*1)+(6*9)+(5*8)+(4*9)+(3*1)+(2*0)+(1*6)=146
146 % 10 = 6
So 19891-06-6 is a valid CAS Registry Number.
19891-06-6Relevant articles and documents
Inhibition of cytopathic effect of human immunodeficiency virus type-1 by various phorbol derivatives
El-Mekkawy, Sahar,Meselhy, Meselhy Ragab,Abdel-Hafez, Atef Abdel-Monem,Nakamura, Norio,Hattori, Masao,Kawahata, Takuya,Otake, Toru
, p. 523 - 529 (2007/10/03)
Forty-eight derivatives of phorbol (9) and isophorbol (14) were evaluated for their inhibition of human immunodeficiency virus (HIV)-1 induced cytopathic effects (CPE) on MT-4 cells, as well as their activation of protein kinase C (PKC), as indices of anti-HIV-1 and tumor promoting activities, respectively. Of these compounds, the most potent inhibition of CPE was observed in 12-O-tetradecanoylphorbol 13-acetate (8) and 12-O-acetylphorbol 13-decanoate (6). The former also showed the strongest PKC activation activity, while the latter showed no activity at 10 ng/ml. Both activities were generally observed in those phorbol derivatives with an A/B trans configuration, but not in the isophorbol derivatives with an A/B cis configuration. Acetylation of 20-OH in the phorbol derivatives significantly reduced the inhibition of CPE, as shown in 12-O-, 20-O-diacetylphorbol 13-decanoate (6a) (IC100=15.6 μg/ml) vs. compound 6 (IC100=0.0076 μg/ml), and 12-O-tetradecanoylphorbol 13,20-diacetate (8a) (IC100=15.6 μg/ml) vs. 12-O- tetradecanoylphorbol 13-acetate (8) (IC100=0.00048 μg/ml), except in the case of 12-O-decanoylphorbol 13-(2-methylbutyrate) (4) and phorbol 12,13-diacetate (9c). The reduction of a carbonyl group at C-3 abruptly reduced the inhibition of CPE, as observed in 3β-hydroxyphorbol 12,13,20-triacetate (9f) (IC100=500 μg/ml) vs. phorbol 12,13,20-triacetate (9d) (IC100=62.5 μg/ml). Although 8 was equipotent in the inhibition of CPE, and activation of PKC, both activities were abruptly decreased by the acetylation of 20-OH and methylation of 4-OH [as in 8a and 4-O-methyl-12-O- tetradecanoylphorbol 13,20-diacetate (8b), respectively]. On the other hand, its positional isomer (12-O-acetylphorbol 13-tetradecanoate (8c) showed neither activities. The removal of a long acyl group in 8 led to a substantial loss of both activities, as shown in phorbol 13-acetate (9b). Of the 12-O-acetyl-13-O-acylphorbol derivatives, the highest inhibition of CPE was observed in 6, which has a dodecanoyl residue at C-13. Both an increase and decrease in the number of fatty acid carbon chains resulted in significant reduction of the inhibition of CPE.
